Maja Maria Porażko

Maja Maria Porażko

Auto-generated profile, based on publicly available information

Maja Maria Porażko

University Clinical Hospital in Opole, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MPMaja Maria Porazko
Maja Maria Porazko
KHKrzysztof Sebastian Habirek
Krzysztof Sebastian Habirek
AŻAnna Katarzyna Żurakowska-Zadrożna
Anna Katarzyna Żurakowska-Zadrożna
KWKamil Andrzej Wiązania
Kamil Andrzej Wiązania
RWRafał Wilczyński
Rafał Wilczyński
MPMichał Mieczysław Parus
Michał Mieczysław Parus
Dermal filler procedures have gained widespread popularity in aesthetic medicine due to their accessibility, relatively low cost, and minimal recovery time. However, with increased demand, reports on complications and adverse reactions have also risen. They range from mild, self-limiting cases to rare, severe, and potentially irreversible outcomes. This article reviews the various types of dermal fillers, their mechanisms of action, and details the spectrum of complications—including local site reactions, complications of aesthetic character, infectious, immune-mediated, and vascular events—while highlighting the importance of correct technique, patient selection, and the constant need for ongoing clinician education. The need for evidence-based protocols and clear guidelines is emphasized to enhance patient safety and optimize outcomes in filler-based aesthetic procedures.

16 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KWKamil A. Wiązania
Kamil A. Wiązania
SWSzymon Wróbel
Szymon Wróbel
RWRafał Wilczyński
Rafał Wilczyński
MPMaja Porażko
Maja Porażko
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses, and sinus tracts, resulting in substantial impairment of quality of life. Advances in the understanding of HS immunopathogenesis have led to the development of biologic therapies targeting key inflammatory pathways, particularly TNF-α and IL-17. To summarize current evidence regarding approved biologic therapies for moderate-to-severe HS, focusing on their mechanisms of action, efficacy, safety, and clinical applicability. A narrative literature review was conducted using the PubMed/MEDLINE database. Studies published between January 2016 and June 2026 were screened using the terms “hidradenitis suppurativa”, “adalimumab”, “secukinumab”, “bimekizumab”, and names of pivotal clinical trials. Randomized controlled trials, extension studies, real-world evidence reports, and high-quality reviews were included. Data were qualitatively synthesized. Adalimumab, the first approved biologic for HS, demonstrated significant efficacy in the phase III PIONEER I and II trials, with sustained long-term benefits. Secukinumab showed superior clinical response rates compared with placebo in the phase III SUNSHINE and SUNRISE studies. Bimekizumab demonstrated promising efficacy in both phase II and phase III BE HEARD trials, improving disease activity, pain, and quality of life. Overall, biologic therapies targeting TNF-α and IL-17 pathways consistently improved clinical outcomes in patients with moderate-to-severe HS. Adalimumab remains the established first-line biologic agent, while secukinumab and bimekizumab provide effective alternatives for patients with poor response to TNF-α inhibition. Despite encouraging efficacy and safety data, complete disease remission remains difficult to achieve, highlighting the need for further therapeutic advances.

11 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AKAnna Kropiwnicka
Anna Kropiwnicka
KHKrzysztof Sebastian Habirek
Krzysztof Sebastian Habirek
MPMaja Maria Porażko
Maja Maria Porażko
AŻAnna Katarzyna Żurakowska-Zadrożna
Anna Katarzyna Żurakowska-Zadrożna
AKAdrianna Krupska
Adrianna Krupska
MPMichał Mieczysław Parus
Michał Mieczysław Parus
Background The rapid evolution of artificial intelligence (AI) technologies has transformed many areas of medicine, including dermatology, where AI-assisted diagnostic systems have demonstrated considerable effectiveness in identifying skin diseases. In contrast, aesthetic dermatology presents additional challenges due to the subjective nature of cosmetic assessments and the absence of universally accepted evaluation standards. Objective This review aims to examine the current role of artificial intelligence in dermatology, with particular emphasis on its application in aesthetic medicine. Furthermore, it evaluates the shortcomings of conventional assessment methods and discusses future opportunities for integrating AI-driven solutions into clinical practice. Methods A narrative review of the literature was conducted to assess the implementation of AI technologies in both medical and aesthetic dermatology. Traditional evaluation approaches, including patient-reported outcome measures and instrument-based skin analysis systems, were reviewed and compared with emerging AI-supported methodologies. Particular attention was given to the limitations of current AI models, dataset quality, and the lack of standardized assessment frameworks. Results Artificial intelligence has achieved notable success in dermatological diagnostics, especially in the detection and classification of skin cancers. Nevertheless, aesthetic dermatology continues to rely heavily on subjective evaluation techniques that often lack reproducibility and standardization. Although AI-based tools are increasingly being introduced into this field, their clinical utility remains constrained by limited dataset diversity, potential algorithmic bias, and variability in assessment protocols. Conclusions The successful implementation of AI in aesthetic dermatology requires the development of standardized evaluation criteria, the creation of comprehensive and ethnically diverse datasets, and improved education of healthcare professionals regarding both the capabilities and limitations of AI technologies. Addressing these challenges may enhance diagnostic consistency, optimize treatment outcomes, and facilitate the broader adoption of AI-driven solutions in aesthetic practice.

28 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JCJulia Anna Czarnecka
Julia Anna Czarnecka
KHKrzysztof Sebastian Habirek
Krzysztof Sebastian Habirek
MPMaja Maria Porażko
Maja Maria Porażko
AŻAnna Katarzyna Żurakowska-Zadrożna
Anna Katarzyna Żurakowska-Zadrożna
AKAdrianna Krupska
Adrianna Krupska
MPMichał Mieczysław Parus
Michał Mieczysław Parus
Laser technologies constitute a fundamental component of contemporary ophthalmology, permitting precise and minimally invasive treatment of refractive errors and selected ocular conditions. The aim of this review is to discuss the most important applications of laser refractive procedures and the Nd:YAG laser. The section on refractive surgery examines photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), and small-incision lenticule extraction (SMILE), with particular emphasis on their mechanisms of action, indications, advantages, limitations, and potential complications. PRK remains a significant method of superficial ablation, especially for patients with thinner corneas or an elevated risk of complications related to flap creation. LASIK provides rapid visual improvement but necessitates a thorough assessment of corneal biomechanics and ocular surface status. SMILE offers a flapless alternative, particularly for correcting myopia and myopic astigmatism. The review also addresses the clinical applications of the Nd:YAG laser, including posterior capsulotomy, peripheral iridotomy, and vitreolysis. The analysis indicates that the effectiveness of laser treatment in ophthalmology is determined not only by technological sophistication but also by appropriate patient selection, outcome assessment, and the surgeon’s expertise.

28 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZMZuzanna Marta Marcinkowska
Zuzanna Marta Marcinkowska
KHKrzysztof Sebastian Habirek
Krzysztof Sebastian Habirek
MPMaja Maria Porażko
Maja Maria Porażko
AŻAnna Katarzyna Żurakowska-Zadrożna
Anna Katarzyna Żurakowska-Zadrożna
AKAdrianna Krupska
Adrianna Krupska
MPMichał Mieczysław Parus
Michał Mieczysław Parus
Hypersomnolence disorders constitute a heterogeneous group of conditions characterized by excessive daytime sleepiness (EDS), impaired alertness, and reduced quality of life. These disorders represent a significant medical and social challenge due to their impact on cognitive functioning, occupational performance, interpersonal relationships, and the increased risk of accidents. The regulation of sleep and wakefulness is a complex process involving interactions between circadian and homeostatic mechanisms, as well as numerous neurotransmitter systems, including orexin, dopamine, serotonin, histamine, acetylcholine, and gamma-aminobutyric acid (GABA). Advances in polysomnography, neuroimaging, and neurophysiology have improved understanding of the mechanisms underlying sleep regulation and central disorders of hypersomnolence. This review summarizes the physiological basis of sleep, current methods used in the assessment of excessive sleepiness, and the clinical characteristics of the major hypersomnolence disorders. Particular attention is given to narcolepsy type 1 and type 2, idiopathic hypersomnia, Kleine–Levin syndrome, and hypersomnia associated with neurological, psychiatric, metabolic, endocrine, inflammatory, vascular, genetic, and traumatic conditions. Diagnostic approaches, including sleep questionnaires, actigraphy, polysomnography, and the Multiple Sleep Latency Test, are discussed in the context of differential diagnosis. The article also reviews current therapeutic strategies, emphasizing both non-pharmacological interventions, such as sleep hygiene, scheduled naps, and behavioral modifications, and pharmacological treatments including modafinil, armodafinil, stimulants, sodium oxybate, pitolisant, and emerging therapeutic approaches targeting the orexin system. Early recognition of hypersomnolence disorders and appropriate management are essential for improving patient outcomes, reducing disease burden, and enhancing overall quality of life.

7 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
RWRafał Wilczyński
Rafał Wilczyński
KWKamil Wiązania
Kamil Wiązania
SWSzymon Wróbel
Szymon Wróbel
FKFilip Kasperczak
Filip Kasperczak
WWWeronika Wrona
Weronika Wrona
MPMaja Porażko
Maja Porażko
Background. Population aging and the growing prevalence of multimorbidity have led to an increasing number of older adults receiving multiple medications. Polypharmacy, commonly defined as the use of five or more medications, is associated with adverse drug reactions, drug interactions, functional decline, hospitalization, and mortality. Age-related physiological changes further increase susceptibility to medication-related harm. Aim. To review the epidemiology, clinical risks, drug interactions, and optimization strategies associated with polypharmacy in elderly patients. Material and methods. A narrative review of the literature was conducted using peer-reviewed articles, clinical guidelines, and consensus documents addressing polypharmacy in adults aged 65 years and older. Evidence related to epidemiology, pharmacological changes associated with aging, adverse drug events, assessment tools, potentially inappropriate medications, and optimization strategies was analyzed and synthesized narratively. Results. Polypharmacy is highly prevalent among older adults, especially those with multimorbidity and frailty. Age-related pharmacokinetic and pharmacodynamic changes increase the risk of adverse drug reactions and clinically significant drug interactions. Common consequences include falls, delirium, cognitive impairment, hospitalization, and increased mortality. Tools such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index help identify inappropriate prescribing. Key optimization strategies include comprehensive geriatric assessment, medication review, deprescribing, and interdisciplinary care. Conclusions. Polypharmacy remains a major challenge in geriatric care. Regular medication review, individualized treatment planning, and deprescribing interventions are essential to reduce medication-related harm and improve clinical outcomes in older adults.